Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia.
Diana Sánchez-CalderónAdriana PedrazaCatalina Mancera UrregoAurelio Mejía-MejíaAna Lorena Montealegre-PáezSandra PerdomoPublished in: ClinicoEconomics and outcomes research : CEOR (2020)
Including liquid biopsy in the treatment of HER2-positive advanced breast cancer was considered currently inapplicable in Colombia because it was not cost effective. Our results open a window of opportunity to improve the development and implementation of ctDNA testing in Colombia, potentially reducing current costs. More evidence is required on the utility of this test, depending on the financial capacity of Colombia and other countries.